ArticlePloS one2017
The neutralizing role of IgM during early Chikungunya virus infection.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 67 citations in OpenAlex.
- Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.JCI insight · 2020Trial
- Article
- Outbreak investigation of reemerging chikungunya virus in Malaysia in 2019-2020.BMC infectious diseases · 2026Article
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- Integrating metagenomics and metatranscriptomics intoThe Journal of general virology · 2026Review
- The First Imported Case of Chikungunya Virus Infection - Anhui Province, China, 2025.China CDC weekly · 2025Article
- Advances and perspectives for animal models of chikungunya virus infection.Biosafety and health · 2025Review
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- Chikungunya virus in Thailand (2020-2023): Epidemiology, clinical features, and genomic insights.PLoS neglected tropical diseases · 2025Article
- Pathogenesis and clinical management of arboviral diseases.World journal of virology · 2025Review
- Activation of CXCR3Journal of virology · 2025Article
- A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.NPJ vaccines · 2024Article
- Receptor Binding Domain-Specific B Cell Memory Responses Among Individuals Vaccinated Against SARS-CoV-2.Vaccines · 2024Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Cryptic circulation of chikungunya virus in São Jose do Rio Preto, Brazil, 2015-2019.PLoS neglected tropical diseases · 2024Article
- Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Cytokine profile, neutralisation potential and viral replication dynamics in sera of chikungunya patients in India: a cross-sectional study.The Lancet regional health. Southeast Asia · 2023Article
- Serological and Molecular Epidemiology of Chikungunya Virus Infection in Vietnam, 2017-2019.Viruses · 2023Article
- Article
- Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection.PLoS pathogens · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibody isotype IgM appears earlier than IgG, within days of onset of symptoms, and is important during the early stages of the adaptive immune response. Little is known about the functional role of IgM during infection with chikungunya virus (CHIKV), a recently reemerging arbovirus that has caused large global outbreaks. In this study, we studied antibody responses in 102 serum samples collected during CHIKV outbreaks in Malaysia. We described the neutralizing role of IgM at different times post-infection and examined the independent contributions of IgM and IgG towards the neutralizing capacity of human immune sera during the early phase of infection, including the differences in targets of neutralizing epitopes. Neutralizing IgM starts to appear as early as day 4 of symptoms, and their appearance from day 6 is associated with a reduction in viremia. IgM acts in a complementary manner with the early IgG, but plays the main neutralizing role up to a point between days 4 and 10 which varies between individuals. After this point, total neutralizing capacity is attributable almost entirely to the robust neutralizing IgG response. IgM preferentially binds and targets epitopes on the CHIKV surface E1-E2 glycoproteins, rather than individual E1 or E2. These findings provide insight into the early antibody responses to CHIKV, and have implications for design of diagnostic serological assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.